Triple-Negative Breast Carcinoma Current and Emerging Concepts

被引:137
|
作者
Schmadeka, Robert [1 ]
Harmon, Bryan E. [1 ]
Singh, Meenakshi [1 ]
机构
[1] SUNY Stony Brook, Sch Med, Dept Pathol, Stony Brook, NY 11794 USA
关键词
Triple negative; Breast cancer; Pathology; Biomarkers; Therapeutic efforts; GROWTH-FACTOR RECEPTOR; BASAL-LIKE SUBTYPE; ESTROGEN-RECEPTOR; 1ST-LINE TREATMENT; ANDROGEN RECEPTOR; MOLECULAR CHARACTERIZATION; PROGESTERONE-RECEPTOR; MEDULLARY CARCINOMA; GENE AMPLIFICATION; CANCER;
D O I
10.1309/AJCPQN8GZ8SILKGN
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Objectives: Triple-negative breast cancer is regarded as an aggressive disease that affects a young patient population and for which effective targeted therapy is not yet available. Methods: Intense efforts have been made to gain a better understanding of this heterogeneous group of tumors from the histologic to the genomic and molecular levels. Results: Progress has been made, including the ability to subtype these tumors and the discovery of biomarkers toward which current therapeutic efforts are focused Many novel targets under exploration have the potential to affect the clinical course of this disease. Conclusions This article reviews the current concepts regarding the clinicopathologic features of triple-negative breast carcinoma, its histologic subtypes, molecular classification, the prognostic and therapeutic potential of biomarkers, and emerging targeted therapies.
引用
收藏
页码:462 / 477
页数:16
相关论文
共 50 条
  • [31] Triple-Negative Breast Cancer: Current Practice and Future Directions
    Costa, Ricardo L. B.
    Gradishar, William J.
    JOURNAL OF ONCOLOGY PRACTICE, 2017, 13 (05) : 301 - +
  • [32] Triple-Negative Breast Cancer: the Current Aspects of Pathogenesis and Therapies
    Mani, Shinjit
    Hande, Abhishek
    Boichuk, Sergei
    BIONANOSCIENCE, 2022, 12 (04) : 1404 - 1435
  • [33] Emerging targeted therapeutic strategies for the treatment of triple-negative breast cancer
    Kumari, Lakshmi
    Mishra, Lopamudra
    Patel, Preeti
    Sharma, Nitin
    Gupta, Ghanshyam Das
    Kurmi, Balak Das
    JOURNAL OF DRUG TARGETING, 2023, 31 (09) : 889 - 907
  • [34] Triple-negative breast cancer: current management and future options
    Conte, PierFranco
    Guarneri, Valentina
    EJC SUPPLEMENTS, 2009, 7 (01): : 14 - 18
  • [35] Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer
    Mediratta, Karan
    El-Sahli, Sara
    D'Costa, Vanessa
    Wang, Lisheng
    CANCERS, 2020, 12 (12) : 1 - 36
  • [36] Triple-Negative Breast Cancer: the Current Aspects of Pathogenesis and Therapies
    Shinjit Mani
    Abhishek Hande
    Sergei Boichuk
    BioNanoScience, 2022, 12 : 1404 - 1435
  • [37] EZH2 expression in triple-negative breast carcinoma
    Al-Wahab, Z.
    Munkarah, A.
    Munns, S.
    Seward, S.
    Sood, A.
    Morris, R.
    Ali-Fehmi, R.
    GYNECOLOGIC ONCOLOGY, 2011, 121 (01) : S61 - S62
  • [38] Triple-negative breast carcinoma: heterogeneity in immunophenotypes and pharmacokinetic behavior
    Vilagran Fraguell, M.
    Sentis Criville, M.
    del Riego Ferrari, J.
    Andreu Navarro, F. J.
    Dalmau Portulas, E.
    Planas Roquerols, J.
    Lluisa Bare, M.
    RADIOLOGIA, 2016, 58 (01): : 55 - 63
  • [39] Molecular Biology Mechanisms and Emerging Therapeutics of Triple-Negative Breast Cancer
    Zhang, Zhiying
    Zhang, Rui
    Li, Donghai
    BIOLOGICS-TARGETS & THERAPY, 2023, 17 : 113 - 128
  • [40] Emerging trends in the treatment of triple-negative breast cancer in Canada: a survey
    Verma, S.
    Provencher, L.
    Dent, R.
    CURRENT ONCOLOGY, 2011, 18 (04) : 180 - 190